News & Updates

Treatment with pembrolizumab plus belzutifan results in a significant and clinically meaningful improvement in disease-free survival (DFS) compared with pembrolizumab monotherapy in patients with clear cell renal cell carcinoma (ccRCC) who are at greater risk of recurrence following nephrectomy, results from the phase III LITESPARK-022 study have shown.

Real-world (RW) data presented at ASCO GU 2026 support the use of enfortumab vedotin plus pembrolizumab (EV+P) as frontline treatment for advanced urothelial carcinoma (UC).

A combination regimen comprising belzutifan and lenvatinib outdoes cabozantinib alone for the treatment of advanced clear cell renal cell carcinoma (ccRCC) in the phase III LITESPARK-011 study.

Addition of palbociclib to maintenance therapy yielded a median progression-free survival (mPFS) approaching 4 years, representing an effective first-line (1L) treatment for patients with hormone receptor–positive (HR+), HER2-positive (HER2+) metastatic breast cancer (mBC), according to the phase III PATINA trial.